A The CX-2029 anti-CD71 Probody drug conjugate has shown first-in-human activity with a strategy that limits off-tumor uptake, and is under continued clinical evaluation [78], following a succesfull preclinical evaluation in preclinical non-human models [137]. The gene discussed is TFRC; the disease is neoplasm.